Literature DB >> 19087121

When drugs and surgery don't work.

Gregory D Cascino1.   

Abstract

Epilepsy is a chronic disorder characterized by recurrent and unprovoked seizures (Dreifuss, 1987; Hauser & Hesdorffer, 1990). It is one of the most common neurologic disorders in the adult. The lifetime risk of developing epilepsy is 3.2% (Mattson, 1992). Approximately 90% of the incident cases in adults have symptomatic partial or localization-related epilepsy (Camfield & Camfield, 1996; Hauser & Hesdorffer, 1990; Hauser, 1992). The medial temporal lobe is the most epileptogenic region of the brain (Luby et al., 1995; Jeong et al., 1999; Wiebe et al., 2001). Pathologic lesions underlying the epileptogenic zone include mesial temporal sclerosis (MTS), tumor, vascular anomaly, malformations of cortical development (MCDs), and head trauma (Cascino et al., 1993; Radhakrishnan et al., 1998). The initial response to medication is of prognostic importance (Hauser, 1992). Patients with a remote symptomatic neurologic disease, foreign-tissue lesion, developmental delay, or abnormal neurologic examination are less likely to be rendered seizure-free. The goals of treatment are to render the individual seizure-free without producing antiepileptic drug (AED) toxicity, allowing the individual to become a participating and productive member of society (Engel & Ojemann, 1993). Despite the introduction of "newer" AEDs, nearly one-half of patients with partial epilepsy will not attain a seizure remission with pharmacotherapy (Kwan & Brodie, 2003). This discussion focuses on management of the adult patient with intractable partial seizure disorders that are medically refractory and may not be surgically remediable. It is estimated that 400,000 of the 2 million individuals with partial epilepsy in the United States have a medically refractory partial seizure disorder (Hauser & Hesdorffer, 1990; Hauser, 1992). An estimated 1,500 patients in the United States undergo epilepsy surgery each year. A UK study indicated that 30,000 patients develop epilepsy each year and approximately 6,000 have medically refractory seizures (Lhatoo et al., 2003). However, there are only about 400 epilepsy surgeries performed annually in the UK. Therefore, the number of patients with intractable partial epilepsy that is both medically refractory and possibly not a surgically remediable epileptic syndrome is significant.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19087121     DOI: 10.1111/j.1528-1167.2008.01930.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  21 in total

1.  Seizure predictors and control after microsurgical resection of supratentorial arteriovenous malformations in 440 patients.

Authors:  Dario J Englot; William L Young; Seunggu J Han; Charles E McCulloch; Edward F Chang; Michael T Lawton
Journal:  Neurosurgery       Date:  2012-09       Impact factor: 4.654

Review 2.  Current prospects and challenges for epilepsy gene therapy.

Authors:  Marc S Weinberg; Thomas J McCown
Journal:  Exp Neurol       Date:  2011-10-08       Impact factor: 5.330

3.  Epileptogenic zone localization using magnetoencephalography predicts seizure freedom in epilepsy surgery.

Authors:  Dario J Englot; Srikantan S Nagarajan; Brandon S Imber; Kunal P Raygor; Susanne M Honma; Danielle Mizuiri; Mary Mantle; Robert C Knowlton; Heidi E Kirsch; Edward F Chang
Journal:  Epilepsia       Date:  2015-04-29       Impact factor: 5.864

4.  The sensitivity and significance of lateralized interictal slow activity on magnetoencephalography in focal epilepsy.

Authors:  Dario J Englot; Srikantan S Nagarajan; Doris D Wang; John D Rolston; Danielle Mizuiri; Susanne M Honma; Mary Mantle; Phiroz E Tarapore; Robert C Knowlton; Edward F Chang; Heidi E Kirsch
Journal:  Epilepsy Res       Date:  2016-01-29       Impact factor: 3.045

Review 5.  Temporal lobe epilepsy and anti glutamic acid decarboxylase autoimmunity.

Authors:  Luca Errichiello; Salvatore Striano; Federico Zara; Pasquale Striano
Journal:  Neurol Sci       Date:  2011-04-06       Impact factor: 3.307

6.  Predictive modeling of EEG time series for evaluating surgery targets in epilepsy patients.

Authors:  Andreas Steimer; Michael Müller; Kaspar Schindler
Journal:  Hum Brain Mapp       Date:  2017-02-16       Impact factor: 5.038

7.  Cellular responses to recurrent pentylenetetrazole-induced seizures in the adult zebrafish brain.

Authors:  Phan Q Duy; Michael A Berberoglu; Christine E Beattie; Charles W Hall
Journal:  Neuroscience       Date:  2017-02-24       Impact factor: 3.590

8.  Myoloid-related protein 8, an endogenous ligand of Toll-like receptor 4, is involved in epileptogenesis of mesial temporal lobe epilepsy via activation of the nuclear factor-κB pathway in astrocytes.

Authors:  Na Gan; Lifen Yang; Ahmed Omran; Jing Peng; Liwen Wu; Fang He; Ciliu Zhang; Qiulian Xiang; Huimin Kong; Yupin Ma; Muhammad Usman Ashhab; Xiaolu Deng; Fei Yin
Journal:  Mol Neurobiol       Date:  2013-08-28       Impact factor: 5.590

Review 9.  Epilepsy and brain tumors.

Authors:  Dario J Englot; Edward F Chang; Charles J Vecht
Journal:  Handb Clin Neurol       Date:  2016

Review 10.  Preclinical insights into therapeutic targeting of KCC2 for disorders of neuronal hyperexcitability.

Authors:  Phan Q Duy; Miao He; Zhigang He; Kristopher T Kahle
Journal:  Expert Opin Ther Targets       Date:  2020-05-05       Impact factor: 6.902

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.